Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Salivary Gland Neoplasms 1Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 3Axitinib 2regorafenib 1avelumab 1amivantamab 1Tretinoin 1Specimen Handling 1Radiation 1Pemetrexed 1Nelfinavir 1Magnetic Resonance Spectroscopy 1Glutamate Carboxypeptidase II 1GSK-3326595 1Etoposide 1Endoscopic Mucosal Resection 1Doxorubicin 1Cisplatin 1Bortezomib 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Adenoid Cystic × Glutamate Carboxypeptidase II × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡